Incyte
INCY
$52.30
Share price
-0.98%
Change (1 day)
-29.13%
Change (1 year)
Categories
P/S ratio for Incyte (INCY)
P/S ratio as of April 2024 (TTM): 3.21
According to Incyte's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.20903. At the end of 2023 the company had a P/S ratio of 3.81.
P/S ratio history for Incyte from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 3.81 | -27.67% |
| 2022 | 5.26 | -3.05% |
| 2021 | 5.43 | -23.99% |
| 2020 | 7.14 | -18.31% |
| 2019 | 8.74 | 21.33% |
| 2018 | 7.21 | -44.61% |
| 2017 | 13.0 | -23.84% |
| 2016 | 17.1 | -36.39% |
| 2015 | 26.9 | 9.95% |
| 2014 | 24.4 | 5.06% |
| 2013 | 23.2 | 211.53% |
| 2012 | 7.46 | -62.82% |
| 2011 | 20.1 | 67.01% |
| 2010 | 12.0 | -89.72% |
| 2009 | 117 | 24.43% |
| 2008 | 93.9 | 280.86% |
| 2007 | 24.7 | 39.05% |
| 2006 | 17.7 | -68.82% |
| 2005 | 56.9 | -26.13% |
| 2004 | 77.0 | 630.92% |
| 2003 | 10.5 | 249.52% |
| 2002 | 3.01 | -49.06% |
| 2001 | 5.92 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 3.71 | 15.59% | 🇨🇭 Switzerland |
 Pfizer PFE | 2.46 | -23.41% | 🇺🇸 USA |
 Eli Lilly LLY | 20.8 | 547.66% | 🇺🇸 USA |
 Amgen AMGN | 5.00 | 55.66% | 🇺🇸 USA |
 Ligand Pharmaceuticals LGND | 9.78 | 204.70% | 🇺🇸 USA |
 Geron GERN | > 1000 | 288,707.83% | 🇺🇸 USA |
 CTI BioPharma
CTIC | 15.8 | 393.03% | 🇺🇸 USA |
 AVEO Oncology
AVEO | 5.53 | 72.28% | 🇺🇸 USA |
 Ardelyx ARDX | 12.0 | 275.20% | 🇺🇸 USA |